Royal Bank of Canada’s Regeneron Pharmaceuticals REGN Stock Holding History

Royal Bank of Canada’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.6M	Buy	+17,600	New	+$13.5M	﹤0.01%	1707
2019 Q3	–	Sell	-4,800	Closed	-$1.5M	–	7035
2019 Q2	$1.5M	Buy	+4,800	New	+$1.6M	﹤0.01%	2974
2017 Q1	–	Sell	-500	Closed	-$184K	–	6791
2016 Q4	$184K	Hold	500	–	–	﹤0.01%	4535
2016 Q3	$201K	Sell	500 -200	-29%	-$80.2K	﹤0.01%	4428
2016 Q2	$245K	Sell	700 -25,000	-97%	-$9.63M	﹤0.01%	4261
2016 Q1	$9.26M	Buy	25,700 +25,200	+5,040%	+$10.4M	0.01%	1428
2015 Q4	$271K	Hold	500	–	–	﹤0.01%	4306
2015 Q3	$233K	Hold	500	–	–	﹤0.01%	4192
2015 Q2	$255K	Hold	500	–	–	﹤0.01%	4178
2015 Q1	$226K	Hold	500	–	–	﹤0.01%	4151
2014 Q4	$205K	Hold	500	–	–	﹤0.01%	4319
2014 Q3	$180K	Hold	500	–	–	﹤0.01%	4262
2014 Q2	$141K	Hold	500	–	–	﹤0.01%	4373
2014 Q1	$150K	Buy	+500	New	+$154K	﹤0.01%	4311

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Royal Bank of Canada's REGN Position: Q1 2026 in Review

Royal Bank of Canada increased its Regeneron Pharmaceuticals (REGN) stake by 1.7% in Q1 2026, buying an estimated $4.56M and bringing the position to 351,171 shares worth $271M. The position accounts for 0.05% of the portfolio, ranked #339.

Royal Bank of Canada first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $275M in Q3 2024. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Royal Bank of Canada held 351,171 shares of Regeneron Pharmaceuticals worth $271M as of Q1 2026.
Royal Bank of Canada bought 5,952 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $4.56M.
Regeneron Pharmaceuticals made up 0.05% of Royal Bank of Canada's portfolio in Q1 2026, its #339 holding.
Royal Bank of Canada first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Royal Bank of Canada's Regeneron Pharmaceuticals position peaked at $275M in Q3 2024.
1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.